Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
None (3) ·
3-MMC (1) ·
4-FA (1) ·
5-APB (1) ·
5-MAPB (1) ·
6-APB (1) ·
6-APDB (1) ·
Butylone (1) ·
Cathinone (1) ·
Ephylone (1) ·
Ethcathinone (1) ·
Ethylone (1) ·
Hexedrone (1) ·
MDA (1) ·
MDAI (1) ·
MDEA (1) ·
MDMA (1) ·
Mephedrone (1) ·
Methcathinone (1) ·
Methylone (1) ·
Mexedrone (1) ·
N-Ethylhexedrone (1) ·
N-Ethylpentedrone (1) ·
Pentedrone (1) ·
PMA (1) ·
PMMA (1)
None (2) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1) ·
MAO inhibitor; monoamine releasing agent (1) ·
MAO inhibitor; serotonin releasing agent (1) ·
Monoamine releasing agent (5) ·
Monoamine releasing agent; 5-HT2A agonist (1) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Serotonin releasing agent (2) ·
Serotonin releasing agent; 5-HT2A agonist (3) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3)
None (25) ·
Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) ·
Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) ·
Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1)
Showing below up to 33 results in range #1 to #33.


